user avatar
Prof. Akiko Iwasaki
@VirusesImmunity
We study antiviral immunity and viral disease pathogenesis. #COVID19 #longCOVID #vaccines @HHMINEWS @YaleIBIO @YaleMed @YaleCII
New Haven, CT
medicine.yale.edu/lab/iwasaki/
Joined May 2017
1,921
Following
211.9K
Followers
Posts
  • Pinned
    user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Dec 27, 2017
    To all aspiring young #WomenInSTEM: Mentee: Should I avoid being pregnant while trying to secure a faculty position? Me: Be pregnant & go on interviews. If they don’t welcome you with open arms and offer childcare options, they don’t deserve you. #KnowYourWorth
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Mar 15, 2020
    For my friends in Turkey 🇹🇷
    user avatar
    İstanbul Gönüllüleri
    @gonulluist
    Mar 15, 2020
    Yale Üniversitesi Tıp Fakültesi'nden İmmünoloji Profesörü Akiko Iwasaki bizler için anlattı! (@VirusesImmunity) 🔴 El yıkamak dışında neler yapabiliriz? 🔴 Grip ile #Covid19 arasındaki farklar ve benzerlikler neler? #Coronavirus #coronaturkiye
    00:00
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Jun 13, 2021
    やっと完成しました。日本の皆様のために、mR N Aワクチンの有効性と安全性についてのビデオを作ってみました。お役に立てると嬉しいです。１日も早く、ワクチンを打って集団免疫を獲得しましょう！リツイートお願いします。
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Jan 29, 2021
    A single-shot J&J Janssen COVID19 vaccine phase 3 results summarized in one table. Great news! Imagine being 💯 protected from death 28 days after a single shot, and 💯 protected from severe disease after 49 days - against all variants. jnj.com/johnson-johnso…
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Mar 13, 2020
    Let's dispel the notion that "novel coronavirus is just like the flu". Sharing this striking comparison of #Flu, #COVID19, #SARS and #MERS made by @BioRender. #COVID19 is 30x more deadly and almost 2x more contagious than the flu. We have no existing immunity to COVID19.
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Aug 24, 2020
    A first case of #COVID19 reinfection from HKU, with distinct virus genome sequences in 1st and 2nd infection (142 days apart). Kudos to the scientists for this study. This is no cause for alarm - this is a textbook example of how immunity should work. (1/n)
    user avatar
    Lilian Cheng
    @cwylilian
    Aug 24, 2020
    #JustIn: #HKU's microbiology team issued a press release suggesting the 33-year-old IT patient, who came back from #Spain, is the world’s first #Covid19 reinfected patient. #Covid19 #coronavirus
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Apr 8, 2020
    When I state my opinion on the immune response to SARS-CoV2 -> you're not an MD, you only treat mice, you are not qualified. When a male PhD states the same opinion -> wow, you are a hero & you look like my uncle 👏🏽 can you take a selfie? I'm tired of this. #WomenInSTEM
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Jan 1, 2021
    My first tweet of 2021 is going to be about 1 dose vs. 2 dose vaccine. I have tweeted in the past of the immunological advantages of a 2 dose vaccine. However, given the enhanced transmission variants on the rise, we need a modified strategy. (1/n)
    The Mutated Virus Is a Ticking Time Bomb
    From theatlantic.com
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Aug 28, 2020
    A 25 yr old patient in Nevada has a confirmed case of #COVID19 reinfection (48 days apart between 1st and 2nd PCR). This time, unlike the case in Hong Kong, the immune system did not protect this person from reinfection or disease. (1/n) papers.ssrn.com/sol3/papers.cf…
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Aug 10, 2022
    Very excited to share our latest research on immunological features of #LongCovid. Our 2+ year collaboration with @PutrinoLab with many other fantastic colleagues and patients - Mount Sinai Yale Long COVID (MY-LC) study by @sneakyvirus1 et al. 🧵(1/)
    medrxiv.org
    Distinguishing features of Long COVID identified through immune profiling
    SARS-CoV-2 infection can result in the development of a constellation of persistent sequelae following acute disease called post-acute sequelae of COVID-19 (PASC) or Long COVID[1][1]–[3][2]. Indivi...
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Jan 2, 2023
    A very important and informative thread about why the Omicron XBB.1.5 subvariant is now dominating in the Northeast US and is expected to spread. Please protect yourselves and others by wearing N95 masks. I am truly concerned about the #longCOVID wave that follows this infection.
    user avatar
    Yunlong Richard Cao
    @yunlong_cao
    Dec 28, 2022
    The superior growth advantage of XBB.1.5 has been well-documented by many colleagues @JPWeiland @LongDesertTrain @EricTopol. Here I'll add some experimental data: 1) XBB.1.5 is equally immune evasive as XBB.1, but 2) XBB.1.5 has a much higher hACE2 binding affinity. 1/
    2M
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Jan 16, 2022
    So excited to be a part of this important study led by @michelle_monje on how significant longterm neurologic damage can occur after a mild respiratory-only SARS-CoV-2 infection. My own🧵on the findings of this study with relevance to #longCovid (1/)
    biorxiv.org
    Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin...
    Survivors of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection frequently experience lingering neurological symptoms, including impairment in attention, concentration, speed of...
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    Sep 25, 2023
    So pleased to report that our Mount Sinai-Yale long COVID (MY-LC) paper with @PutrinoLab & others is now published!! Proud of the hard work of all who contributed. We found biological signatures that can distinguish people with vs. without #longCOVID (1/) nature.com/articles/s4158…
    1.1M
  • user avatar
    Prof. Akiko Iwasaki
    @VirusesImmunity
    May 16, 2022
    It’s time to invest in next generation COVID vaccines that not only prevent severe disease but also block infection and transmission. It makes sense to induce mucosal immunity to fight a mucosal viral infection. My opinion in @nytimes today👇🏽
    Opinion | The Answer to Stopping the Coronavirus May Be Up Your Nose (Published 2022)
    From nytimes.com